Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of EDP-938 in high-risk non-hospitalized adults with acute RSV infection
2022-002215-29Phase 2Active
- Sponsor
- Enanta Pharmaceuticals, Inc.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing EDP-938 with Placebo (2 arms). Primary endpoint: Time to resolution of RSV LRTD symptoms. Started Oct 2022; status: active.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2022-002215-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002215-29.